Immunome Inc. Files 8-K: Other Events & Exhibits
Ticker: IMNM · Form: 8-K · Filed: Dec 17, 2025 · CIK: 1472012
| Field | Detail |
|---|---|
| Company | Immunome Inc. (IMNM) |
| Form Type | 8-K |
| Filed Date | Dec 17, 2025 |
| Risk Level | low |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.0001, $21.50, $400 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: sec-filing, 8-k, regulatory-update
TL;DR
Immunome filed an 8-K on Dec 17 for Dec 16 events - mostly procedural updates.
AI Summary
Immunome Inc. filed an 8-K on December 17, 2025, reporting on events that occurred on December 16, 2025. The filing is primarily an "Other Events" and "Financial Statements and Exhibits" report, with no specific material event detailed in the provided text.
Why It Matters
This 8-K filing indicates Immunome Inc. is providing updates or submitting required documentation to the SEC, which could contain important operational or financial information.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not disclose any specific material events that would inherently increase risk.
Key Numbers
- 001-39580 — SEC File Number (Identifies the company's filing history with the SEC.)
- 77-0694340 — EIN (Employer Identification Number for tax purposes.)
Key Players & Entities
- Immunome Inc. (company) — Registrant
- December 16, 2025 (date) — Earliest event reported
- December 17, 2025 (date) — Date of report
- Delaware (jurisdiction) — State of incorporation
- Bothell, WA (location) — Principal executive offices
FAQ
What specific "Other Events" are being reported by Immunome Inc. in this 8-K filing?
The provided text does not specify the details of the "Other Events" beyond listing it as an item information category.
What "Financial Statements and Exhibits" are included with this 8-K filing?
The filing indicates "Financial Statements and Exhibits" are included, but the specific contents are not detailed in the provided header information.
What is the significance of the filing date being December 17, 2025, for events on December 16, 2025?
This indicates the report is filed promptly after the event, as required by SEC regulations for material information.
Where are Immunome Inc.'s principal executive offices located?
Immunome Inc.'s principal executive offices are located at 18702 N. Creek Parkway, Suite 100, Bothell, WA 98011.
What is Immunome Inc.'s standard industrial classification?
Immunome Inc.'s standard industrial classification is Pharmaceutical Preparations [2834].
Filing Stats: 1,118 words · 4 min read · ~4 pages · Grade level 11.2 · Accepted 2025-12-17 16:49:25
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IMNM The Nasdaq
- $21.50 — price to the public in the offering was $21.50 per share. All of the shares of Common
- $400 m — from the offering will be approximately $400 million, before deducting underwriting di
Filing Documents
- d27244d8k.htm (8-K) — 32KB
- d27244dex11.htm (EX-1.1) — 222KB
- d27244dex51.htm (EX-5.1) — 9KB
- d27244dex991.htm (EX-99.1) — 9KB
- d27244dex992.htm (EX-99.2) — 10KB
- g27244g1217075353891.jpg (GRAPHIC) — 2KB
- g27244g1217075558189.jpg (GRAPHIC) — 3KB
- g27244g1217075718767.jpg (GRAPHIC) — 3KB
- 0001193125-25-322877.txt ( ) — 482KB
- imnm-20251216.xsd (EX-101.SCH) — 3KB
- imnm-20251216_lab.xml (EX-101.LAB) — 18KB
- imnm-20251216_pre.xml (EX-101.PRE) — 11KB
- d27244d8k_htm.xml (XML) — 4KB
Forward Looking Statements
Forward Looking Statements Certain statements contained in this report regarding the Company's expectations regarding the offering are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are based upon the Company's current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, the Company's expectations regarding the market conditions, the satisfaction of customary closing conditions related to the offering and the Company's ability to complete the offering. These and other risks and uncertainties are described in greater detail in the section entitled "Risk Factors" in the Company's most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in the Company's other filings with the SEC, including those contained or incorporated by reference in the preliminary prospectus supplement and accompanying prospectus related to the offering filed with the SEC. All forward-looking statements contained in this report speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law. Item9.01 Financial Statements and Exhibits. (d) Exhibits. Exhibit No. Description 1.1 Underwriting Agreement by and among the Company, Leerink Partners LLC, J.P. Morgan Securities LLC, TD Securities (USA) LLC, Goldman Sachs & Co. LLC, and Guggenheim Securities, LLC, dated December 16, 2025. 5.1 Opinion of Cooley LLP. 23.1
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Immunome, Inc. Dated: December 17, 2025 By: /s/ Max Rosett Max Rosett Chief Financial Officer